Mgr. Michal Šmída, Dr. rer. nat.
Research Group Leader Junior, Michal Šmída Research Group
office: bldg. E35/186
Kamenice 753/5
625 00 Brno
phone: | +420 532 23 5494 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 78
2019
-
Epigenetic drug screen on CD20 immunotherapy resistant cells revealed possible role of Aurora kinase inhibitors in CD20 expression regulation.
Year: 2019, type: Conference abstract
-
Performance of α-CD19 Chimeric Antigen Receptor T cells in genetically defined classes of Chronic Lymphocytic Leukemia
Year: 2019, type: Conference abstract
-
Revoluce v imunoterapii nádorů: CAR-T lymfocyty
Year: 2019, type: Conference abstract
2018
-
ASH 2017 – novinky laboratorní.
Year: 2018, type:
-
CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia
Year: 2018, type: Conference abstract
-
Dědičné trombocytopenie
Transfuze a Hematologie Dnes, year: 2018, volume: 24, edition: 1
-
Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets
Year: 2018, type: Conference abstract
-
Epigenetic drug screen on resistant CLL cells reveals Aurora kinase inhibitors as enhancers of CD20 expression and sensitizers to treatment with CD20 monoclonal antibodies
Year: 2018, type: Conference abstract
-
Epigenetic drug screen on rituximab-resistant cells revealed in unexpected role of Aurora kinase inhibitors in CD20 expression
Year: 2018, type: Conference abstract
-
Epigenetický screening buněk rezistentních k rituximabu odhalil možnou roli inhibitorů Aurora kináz v regulaci exprese CD20
Year: 2018, type: Conference abstract